China

Mar 21, 2019

Biohaven buys PRV from GW Pharmaceuticals for USD 105 million GW Pharmaceuticals has announced its decision to sell its rare pediatric disease priority review voucher (PRV) to Biohaven Pharmaceuticals. The voucher was issued under U.S. Food and Drug Administration programme to accelerate speedy recovery of rare ...

Mar 11, 2019

Technology has made an impact on every field. And Healthcare is no exception. Advances in medical technology have proven to be a game-changer in the health sector. But is the case same when Women healthcare comes to mind? It will not be less than a shock to learn that Women were not included in medical research and...

Aug 27, 2018

As part of its “Made in China 2025” industrial plan, China hopes to reinvent its pharmaceutical industry. President Xi Jinping has identified his country’s reliance on foreign drug imports as a critical concern. China’s enormous population, coupled with the rise of disease and illness, make the country a prime marke...

Nov 07, 2017

Teva looks to sell generics in China through joint venture with Guangzhou Pharma As the world’s largest generics maker, Teva still doesn’t have much of a presence in China, even though it is a country relies heavily on generics. The Israeli company is looking to remedy that as Teva has said it “has no agreement with...

Jul 07, 2015

DelveInsight expertise over 400+ Indication Active Pharmaceutical Ingredient (API) Reports DelveInsight, leading Market Research and Business Consulting firm has an expertise in providing business solutions to Pharma and biotech companies. DelveInsight has 400+ Indication API reports on wide range of therapeutic ...

Aug 01, 2014

“If a market is growing enormously, you need to understand what’s nourishing it” DelveInsight has launched its Reports under two brands Pharm Delve and Pharm Insights. Pharm Delve reports are known for its extensive detailed information of the Marketed drugs- Global Market, API Market & Manufacturer...